论文部分内容阅读
[目的]分析化疗联合吉非替尼小分子靶向疗法在肺癌患者中的疗效及安全性。[方法]肺癌患者100例,参照抽签法分为对照组和试验组,每组50例,对照组予以常规化疗,试验组基于对照组予以吉非替尼小分子靶向治疗,对比两组患者治疗后血清肿瘤标志物水平[鳞状细胞癌抗原(SCCA)、细胞角蛋白19片段(CYERA21-1)癌胚抗原(CEA)]及临床疗效、不良反应。[结果]治疗后,试验组血清肿瘤标志物SCCA(2.86±0.50)ng/L、CYERA21-1(3.06±0.92)ng/l、CEA(16.53±2.11)mg/ml分别低于对照组SCCA(3.72±0.68)ng/L、CYERA21-1(4.43±1.10)ng/L、CEA(27.38±2.50)mg/ml,差异有统计学意义(P均<0.05);试验组总有效率66.00%(33/50)高于对照组38.00%(19/50),差异有统计学意义(Z=7.850,P=0.005);两组总不良反应率比较差异无统计学意义(P>0.05)。[结论]化疗联合吉非替尼小分子靶向治疗对肺癌患者疗效确切,能够显著降低血清肿瘤标志物水平,安全性较好。
[Objective] To analyze the efficacy and safety of chemotherapy combined with gefitinib small molecule targeted therapy in patients with lung cancer. [Methods] One hundred patients with lung cancer were divided into control group and trial group according to the method of drawing lottery, 50 cases in each group. The control group received routine chemotherapy. The control group received gefitinib small molecule targeted therapy. Serum levels of tumor markers [SCCA, CYERA21-1 CEA] after treatment, and clinical efficacy, adverse reactions. [Results] The levels of serum tumor markers SCCA (2.86 ± 0.50) ng / L, CYERA21-1 (3.06 ± 0.92) ng / l and CEA (16.53 ± 2.11) mg / ml in the experimental group were significantly lower than those in the control group 3.72 ± 0.68 ng / L, CYERA21-1 (4.43 ± 1.10) ng / L and CEA (27.38 ± 2.50) mg / ml, the difference was statistically significant (all P <0.05); The total effective rate was 66.00% 33/50) were higher than that of the control group (38.00%, 19/50), the difference was statistically significant (Z = 7.850, P = 0.005). There was no significant difference in the total adverse reaction rate between the two groups (P> 0.05). [Conclusion] Chemotherapy combined with gefitinib small molecule targeted therapy has definite curative effect on patients with lung cancer, can significantly reduce the level of serum tumor markers and is safe.